Hard to Treat Diseases' (HTDS.PK) Update on Various Business Activities
SHENZHEN, China, Nov. 11 /PRNewswire-FirstCall/ - Hard to Treat Diseases (HTDS.PK) www.htdsmedical.com is using this opportunity to update the shareholders and the public on the development of several previously announced events, namely Q3 financials, Intellectual Property Rights, the pending EU merger, and HTDS' Pink Sheets "skull and bones" rankings.
Regarding the HTDS' Q3 financials, HTDS will file the Q3 financials on Pink Sheets by the due date of November 15, 2009. The company will also follow up with a brief news update of the financials, including the progress of H1N1 of Mellow Hope, the positive future prospects HTDS management foresees with the upcoming Novartis acquisition of 85% stake in HTDS' H1N1 Vaccine partner, Zhejiang Tianyuan Bio-Pharmaceutical Co, thus by default Novaris becoming the new partner. The research progress of its Slavica Bio Chem subsidiary, Cancer Mind Up project and its www.mindupbioresearch.com website which the company will launch this week.
The Intellectual Property (IP) dispute with Blue Earth Solutions (BESN) namely the Styro-Solve product, HTDS management can report that its negotiations continue. HTDS management is hopeful for a mutually beneficial settlement.
The HTDS' merger negotiations with the EU based stem cell research company are well underway. The HTDS representatives have scheduled meetings, and the start of Due Diligence for November 23-25, 2009. HTDS management is exploring various options of this lucrative deal. The scenario which HTDS management is currently favoring includes a hybrid of technology - revenue sharing model. This it would achieve through its Slavica Bio Chem subsidiary which would earn HTDS licensing revenues. This hybrid mechanism merger would leave HTDS' share structure undisturbed while at the same time HTDS' would earn fees for technology and services exchanged.
Lastly, HTDS addresses the issue of the Naked Short Sellers again. HTDS is working continuously with Pink Sheets to resolve the issue as it affects the HTDS' ranking on Pink Sheets. The ranking still warns buyers that the stock is under siege, and restricts certain normal trading activities of the security.
Lastly, regarding HTDS' audited statements and its aspirations of up listing to OTCBB, an auditor is currently engaged on completing HTDS' 2007-2008 financials. Audited statements are one of the requirements the company must obtain to meet the OTCBB listing threshold. HTDS management does not foresee any issues in meeting the audit requirements. HTDS management has a prearranged OTCBB vehicle already ready formulated and capitalized for its operating subsidiaries and the soon to be announced merger up list to OTCBB.
To receive future updates via email, including quarterly newsletters and company updates that may not be newsworthy, however important to the reader and followers of the company, please sign up today free at www.minamargroup.com/updates
Safe Harbor Statement
Information in this news release may contain statements about future expectations, plans, prospects or performance of Hard to Treat Diseases Inc. that constitute forward-looking statements for purposes of the Safe Harbor Provisions under the Private Securities Litigation Reform Act of 1995. The words or phrases "can be", "expects", "may affect", "believed", "estimate", "project" and similar words and phrases are intended to identify such forward-looking statements. Hard to Treat Diseases Inc. cautions you that any forward-looking information provided by or on behalf of Hard to Treat Diseases Inc. is not a guarantee of future performance. None of the information in this press release constitutes or is intended as an offer to sell securities or investment advice of any kind. Hard to Treat Diseases Inc.'s actual results may differ materially from those anticipated in such forward-looking statements as a result of various important factors, some of which are beyond Hard to Treat Diseases Inc.'s control. In addition to those discussed in Hard to Treat Diseases Inc.'s press releases, public filings, and statements by Hard to Treat Diseases Inc.'s management, including, but not limited to, Hard to Treat Diseases Inc.'s estimate of the sufficiency of its existing capital resources, Hard to Treat Diseases Inc.'s ability to raise additional capital to fund future operations, Hard to Treat Diseases Inc.'s ability to repay its existing indebtedness, the uncertainties involved in estimating market opportunities, and in identifying contracts which match Hard to Treat Diseases Inc.'s capability to be awarded contracts. All such forward-looking statements are current only as of the date on which such statements were made. Hard to Treat Diseases Inc. does not undertake any obligation to publicly update any forward-looking statement to reflect events or circumstances after the date on which any such statement is made or to reflect the occurrence of unanticipated events.
CONTACT: For any investor relations matters, please contact www.minamargroup.net/helpdesk; Investor Relations Department Inquiry, www.minamargroup.net (IR); For (M&A) and Corporate Matters, www.minamargroup.com
Q3 Financials, EU Stem Cell Merger, MindUp Cancer Project, Pink Sheets Ranking
SOURCE Hard to Treat Diseases
You May Also Like